On the other hand, our results also demonstrated that MYSM1 accelerates cell proliferation even in the absence of E2, suggesting that MYSM1 may also participate in regulating non-canonic ERα signaling pathway independent on E2 treatment to participate in promoting breast cancer process (Fig. 5A,B). Here, MYSM1 is linked to breast carcinoma.